White paperThe Enterprise Framework for Compliant, Scalable AI
Download now
GovernanceContinuous complianceData

Improved UDI Data Integrity with Single-Source-of-Truth

Case study on Improved UDI Data Integrity with Single-Source-of-Truth.

Client profile: Global manufacturer of biotech, pharma, medical device consumer products, and supplements managing 300k products across 60+ systems.

Improved UDI Data Integrity with Single-Source-of-Truth graphic

Executive takeaway

USDM replaced multiple siloed data repositories with a single, scalable product master data model that protects UDI data integrity, supports billions of data points for future growth, and saves $500k annually through IT system optimization.

Annual Savings

$500k

Saved annually from IT system optimization and decommissioning redundant systems.

Data Growth Absorbed

>3,000%

Exponential growth in product data points from future UDI regulatory and customer requirements, scaled to billions of data points.

Planning Horizon

15 years

Collaborated with 20+ key stakeholders to inventory expected data attributes over a 15-year time horizon.

Before USDM

  • Inability to provide timely product master data, a significant threat to commercial operations.
  • Multiple siloed, inconsistent data repositories with no central single-source-of-truth.
  • Processes and systems that could not scale to absorb >3,000% data growth across 300k products and 60+ systems.

After USDM

  • A single-source-of-truth for all product master data that protects data integrity.
  • A scalable data model proven to manage billions of data points and future growth.
  • $500k saved annually after decommissioning several redundant systems.

Enabling Rapid Growth with a Single-Source-of-Truth

USDM partnered with a global manufacturer of biotech, pharma, and medical device consumer products to revamp its data management processes and enable rapid growth by creating a single-source-of-truth. Your data is your most significant IP, and an ever-changing regulatory landscape demands a future-proof strategy that protects data integrity in life sciences.

The Challenge

A global manufacturer of biotech, pharma, med-dev consumer products, and supplements faced a data crisis that threatened its commercial operations:

  • The inability to provide timely product master data was a significant threat to commercial operations.
  • >3,000% exponential growth in product data points was expected from future UDI regulatory and customer requirements.
  • 300k products plus 100k new products annually across 60+ systems meant billions of data points to be managed with no central single-source-of-truth.
  • Multiple siloed, inconsistent data repositories created risk and rework.
  • Existing processes and systems could not scale for growth.

Meeting UDI obligations under evolving requirements such as 21 CFR Part 11 made a trustworthy, governed data foundation non-negotiable.

The Approach

USDM applied a structured, risk-based 4-step process to address the global UDI need:

  1. Assessment
  2. Roadmap
  3. Select & Acquire
  4. Build and Deploy

What we did

  • Collaborated with 20+ key stakeholders to inventory expected data attributes and data point needs over a 15-year time horizon.
  • Partnered with IT to develop a scalable data model to capture, organize, and model the attributes, then ran simulations to verify the design.
  • Developed a roadmap to roll out the data model, outlining a risk-based, phased approach consistent with a continuous compliance mindset.
  • Implemented the new data model in the existing system and confirmed it was capable of managing global needs, making it the single-source-of-truth for all product master data.
  • Gathered and loaded several million new data points to meet current regulations and customer needs.
  • Decommissioned several systems to reduce cost and complexity.

Designing the model with built-in governance also strengthened the client's posture for computer software assurance as the platform validation footprint evolves.

The Results

  • Single-source-of-truth realized to protect data integrity.
  • Achieved scale to support billions of data points and future growth.
  • $500k saved annually from IT system optimization.

By consolidating siloed repositories into one governed, scalable data model, USDM turned a threat to commercial operations into a future-proof foundation for UDI compliance and growth. Explore how a disciplined approach to data integrity in life sciences can protect your most valuable IP, or contact us to start the conversation.

Data Integrity for Life Sciences

Build your single-source-of-truth for UDI and product master data

Siloed, inconsistent data repositories put your commercial operations and UDI compliance at risk. USDM designs scalable, future-proof data models that protect data integrity and absorb exponential growth. Let's map your path to a single-source-of-truth.

Talk to a data integrity expert

Go deeper

Related guidance

Blogs, webinars, and white papers on the capabilities behind this outcome.

White Paper

Transformative Outcomes in Life Sciences

A practical white paper on using PTC ThingWorx, IoT, AI, and digital twins to connect GxP manufacturing, lab, and quality operations — improving product quality, reducing downtime, and strengthening data integrity without increasing regulatory risk.

Read
Blog

Evaluating Google Agentspace for Life Sciences

A practical 10-factor framework for life sciences teams evaluating Google Agentspace—covering GxP compliance, data security, auditability, multi-agent governance, and ROI for confident, validated AI adoption.

Read
Webinar

NetSuite for GxP, Regulated Use Cases

Watch this on-demand webinar to see how life sciences organizations use NetSuite for GxP-regulated processes — from item and material management to 21 CFR Part 11 e-records, audit trails, and e-signatures — and how USDM reduces the compliance burden.

Read
Blog

Key differences in the requirements for SFDA UDI and US & EU UDI

Manufacturers with U.S. and EU UDI-compliant medical devices face new requirements under Saudi Arabia's SFDA MDS-G34 guidance. Learn the key differences across the U.S., EU, and SFDA Unique Device Identification systems and what changes you need for SAUDI-DI compliance.

Read
Blog

More Medical Device Implications of Brexit

Brexit reshaped how medical devices reach the UK market. Learn the MHRA registration deadlines, UK Responsible Person rules, and the shift from CE marking to UKCA and UK(NI) marks for Great Britain and Northern Ireland.

Read
Blog

Most Misunderstood and Misapplied UDI Requirements

A clear breakdown of the most misunderstood UDI rules—Direct Marking under FDA 801.45(a), what "reprocessed before each use" really means, and why a device's label is a regulatory concept, not a sticker.

Read

Start here

Put AI to work in life sciences — with the right guardrails underneath.

Start with a structured AI Readiness Assessment: fixed-fee, executive-ready, and built to surface the highest-value workflows first.

Start here

Talk to USDM

Tell us what workflow or outcome you want to improve and we'll map the right AI, governance, and delivery path.

By submitting this form, you agree to USDM’s Privacy Policy and consent to receive communications from USDM. You can unsubscribe at any time using the link in our emails.